-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) announced that recently, the company's subsidiaries, Suzhou Shengdia Biomedical Co., Ltd., and Shanghai Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for SHR-4610 injections, SHR-1826 for injections, SHRA2009 for injections, and SHR-8068 injections, which will conduct clinical trials in the near future.

Zhitongcaijing·07/27/2026 14:57:16
Listen to the news
Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) announced that recently, the company's subsidiaries, Suzhou Shengdia Biomedical Co., Ltd., and Shanghai Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for SHR-4610 injections, SHR-1826 for injections, SHRA2009 for injections, and SHR-8068 injections, which will conduct clinical trials in the near future.